Efficacy of desensitization decoction combined with sanzi yangqin decoction and montelukast in treating children with cough variant asthma
Liu Ting-ting
Yuan Shu-gao
Wang Pan-pan
Ma Zhi-ping
Liu Zhi-min
Tian Qian
Abstract：Objective To investigate the efficacy of desensitization decoction combined with sanzi yangqin decoction and montelukast sodium tablets in treatment of child patients with cough variant asthma(CVA)caused by wind phlegm in the lungs.Methods A total of 104 child patients with CVA admitted to Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from November 2021 to October 2023 were included and divided into two groups using the random number method,with 52 in each group.The patients in the control group received routine treatment with montelukast sodium,and those in the observation group received desensitization decoction and sanzi yangqin decoction in addition.The clinical efficacy,CVA related scores(cough symptom score,TCM syndrome score,cough questionnaire score(LCQ)),lung function indicators(forced expiratory volume in first second(FEV1),forced expiration)were compared between the two groups.Meanwhile,the vital capacity(FVC),peak expiratory flow rate(PEF)),inflammatory indicators(eosinophil count(EOS),interleukin 13(IL-13),tumor necrosis factor alpha(TNF-α)),the incidence of adverse reactions and the time of cough symptom relief and the time of stopping montelukast sodium were also compared.Results The observation group reported a higher clinical efficacy rate compared to control group(94.23%(49/52)vs 78.85%(41/52),χ2=5.283,P<0.05).After treatment,the TCM syndrome scores and cough symptom scores of the two groups were reduced,and LCQ was increased,and the observation group((4.49±1.25)points,(1.51±0.42)points,(15.87±3.47)points)improved better than the control group((6.56±1.87)points,(1.73±0.56)points,(14.52±3.28)points)(t=6.636,2.266,2.039,all P<0.05).FEV1,FVC,and PEF increased in the two groups,and they were higher in the observation group((93.87±10.88)%,(95.89±8.25)%,(95.37±8.33)%)than in the control group((87.54±10.05)%,(87.66±9.27)%,(90.69±8.28)%,respectively)(t=3.081,4.782,2.873,all P<0.05).The EOS,IL-13,and TNF-α decreased in the two groups,and they were lower in the observation group((0.39±0.11)×109·L-1,(106.51±8.42)ng·L-1,(5.56±1.23)pg·mL-1)than in the control group((0.44±0.13)×109·L-1,(112.83±8.65)ng·L-1,(6.12±1.48)pg·mL-1)(t=2.117,3.775,2.098,all P<0.05).No statistical difference was found in adverse reaction rate between the two groups(χ2=0.443,P>0.05).The time of cough symptom relief and the time of stopping montelukast sodium in the observation group((8.13±1.94)d,(21.42±2.80)d)were lower than those in the control group((10.56±2.35)d,(24.86±2.65)d)(t=5.750,6.435,both P<0.05).Conclusion The treatment usng desensitization decoction in combination with sanzi yangqin decoction and montelukast sodium tablets has a good therapeutic effect on children with CVA of wind-phlegm lurking in the lung.It can improve lung function,reduce inflammation level,improve quality of life and reduce drug dependence on the basis of ensuring safety.
Keywords：Desensitization decoctionSanzi Yangqin decoctionWind phlegm and lung syndromeCough variant asthmaClinical efficacy
Publication Date：2025-04-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 347-351 )